Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa

FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ

Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).

Leia mais: FDA grants orphan drug designation to Plus Therapeutics’ REYOBIQ
Grafa

Bausch + Lomb secures FDA clearance for advanced vitrectomy technology

Bausch + Lomb (NYSE:BLCO), a leader in eye health, announced on April 8, 2026, that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Bi-Blade+ dual-port vitrectomy cutter and an advanced Adaptive Fluidics update for the Stellaris Elite® Vision Enhancement System.

Leia mais: Bausch + Lomb secures FDA clearance for advanced vitrectomy technology
Grafa

FDA grants breakthrough RMAT designation to United Therapeutics’ bioengineered liver assist product

United Therapeutics (NASDAQ:UTHR), a leader in regenerative medicine and organ manufacturing, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational miroliverELAP®.

Leia mais: FDA grants breakthrough RMAT designation to United Therapeutics’ bioengineered liver assist product
Grafa
Health

Nurix Therapeutics advances Bexobrutinib toward Phase 3 following strong Q1

Nurix Therapeutics (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on small molecule therapies for cancer and immune disorders, reported its first-quarter 2026 financial results and provided a comprehensive update on its lead clinical programs on April 8, 2026.

Leia mais: Nurix Therapeutics advances Bexobrutinib toward Phase 3 following strong Q1
Grafa

AtaiBeckley reports rapid and durable antidepressant response in Phase 2a trial of BPL-003

AtaiBeckley (NASDAQ:ATAI), a clinical-stage biopharmaceutical company developing next-generation mental health treatments, reported on April 8, 2026, peer-reviewed Phase 2a results demonstrating that a single intranasal dose of BPL-003 achieved rapid and sustained clinical benefits in patients with Treatment-Resistant Depression (TRD).

Leia mais: AtaiBeckley reports rapid and durable antidepressant response in Phase 2a trial of BPL-003
Grafa
Technology

ECARX announces preliminary plan to acquire FlyMe OS intellectual property assets

ECARX Holdings (NASDAQ:ECX), a global leader in automotive intelligence technology, announced on April 8, 2026, that its Board of Directors has approved a preliminary plan to pursue the acquisition of a minority interest and specific intellectual property assets related to FlyMe OS.

Leia mais: ECARX announces preliminary plan to acquire FlyMe OS intellectual property assets